Sioux Falls-based SAB Biotherapeutics has received an additional $35.6 million in government funding, plus $14 million in series B funding that includes a new investor – global health care leader Merck.
Sioux Falls-based SAB Biotherapeutics has received an additional $35.6 million in government funding, plus $14 million in series B funding that includes a new investor – global health care leader Merck.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
